SGMT
NASDAQSagimet Biosciences Inc.
Price$7.04+0.00 (+0.00%)
01:45 PM07:45 PM
News · 26 weeks54+44%
2025-12-072026-05-31
Mix2990d
- SEC Filings13(45%)
- Other7(24%)
- Insider6(21%)
- Analyst1(3%)
- Leadership1(3%)
- Earnings1(3%)
Latest news
25 items- SECSagimet Biosciences Inc. filed SEC Form 8-K: Financial Statements and Exhibits8-K - Sagimet Biosciences Inc. (0001400118) (Filer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Chauche Thierry4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
- INSIDERSEC Form 4 filed by Chief Medical Officer Grauer Andreas4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
- INSIDERSEC Form 4 filed by Chief Legal & Admin. Officer Rozek Elizabeth4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
- INSIDERSEC Form 4 filed by President & CEO Happel David4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
- PRSagimet Biosciences Presents Two Posters at EASL 2026 on Denifanstat/Resmetirom Combination in MASHPhase 1 clinical data poster selected as a Best of EASL 2026 presentation Combination of denifanstat and resmetirom was generally well-tolerated in Phase 1 clinical trial Phase 1 data show rapid reductions in cholesterol levels, suggesting the potential for a cardiovascular benefit SAN MATEO, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced the presentation of two posters at the European Association for the Study of the Liver (EASL) Annual Congress 2026, being held in Barcelona, Spain on May 27-30, 2026. The La
- INSIDERSEC Form 4 filed by Chief Medical Officer Grauer Andreas4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
- INSIDERSEC Form 3 filed by new insider Grauer Andreas3 - Sagimet Biosciences Inc. (0001400118) (Issuer)
- PRSagimet Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQSAN MATEO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ on Tuesday, May 19, 2026, in New York, NY with a fireside chat at 2pm ET (link here). A webcast of the fireside chat will be available in the Investors & Media section of Sagimet's website at www.sagimet.com, with an archived replay available for 90 days following the live event. About Sagimet Biosciences Sagimet is a clinical-stage biopharmaceut
- SECSagimet Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Sagimet Biosciences Inc. (0001400118) (Filer)
- SECSEC Form 10-Q filed by Sagimet Biosciences Inc.10-Q - Sagimet Biosciences Inc. (0001400118) (Filer)
- PRSagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate UpdatesSecured equity financing with gross proceeds of $175M in April 2026 Phase 3 clinical trial of denifanstat in moderate to severe acne patients for the U.S. planned to initiate in second half of 2026 First-in-human Phase 1 clinical trial of FASN inhibitor TVB-3567 ongoing Cumulative cash, cash equivalents and marketable securities expected to fund current operations through 2028, including through data readout of denifanstat Phase 3 trial in moderate to severe acne SAN MATEO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, toda
- PRSagimet Biosciences to Present Mechanism of Action Data for its FASN Inhibitors at the Society for Investigative Dermatology in ChicagoPre-clinical data shows potential for FASN inhibition as mechanism of action to treat acne Phase 3 clinical trial of denifanstat in moderate to severe acne patients for the U.S. planned to initiate in second half of 2026 SAN MATEO, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that the Company will present a poster at the 83rd Society for Investigative Dermatology Annual Meeting (SID 2026) on May 15, 2026 showing in vitro data that supports the potential use of FASN inhibitors in acne. "Excess sebum producti
- SECSagimet Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - Sagimet Biosciences Inc. (0001400118) (Filer)
- SECSEC Form 424B5 filed by Sagimet Biosciences Inc.424B5 - Sagimet Biosciences Inc. (0001400118) (Filer)
- SECSagimet Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Sagimet Biosciences Inc. (0001400118) (Filer)
- PRSagimet Biosciences Announces Pricing of $175.0 Million Underwritten Offering of Series A Common StockSAN MATEO, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced the pricing of an underwritten offering of 29,166,700 shares of its Series A common stock at a price of $6.00 per share. The gross proceeds from the offering are expected to be approximately $175.0 million, before deducting underwriting discounts and commissions and other offering expenses. All of the shares in the offering are to be sold by Sagimet. The offering is expected to close on or about April 28, 2026, subject to the satisfaction of customary cl
- SECSagimet Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Sagimet Biosciences Inc. (0001400118) (Filer)
- PRSagimet Biosciences Provides Strategic and Corporate UpdatesPhase 3 clinical trial of denifanstat in moderate to severe acne patients for the U.S. planned to initiate in second half of 2026 First-in-human Phase 1 clinical trial of FASN inhibitor TVB-3567 ongoing Further MASH development to be undertaken only upon securing non-dilutive funding Sagimet to host a KOL event and webcast, April 30 at 2 pm ET SAN MATEO, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today provided strategic and corporate updates. "Building on the recent successful Phase 3 clinical trial in China of our
- SECSEC Form DEF 14A filed by Sagimet Biosciences Inc.DEF 14A - Sagimet Biosciences Inc. (0001400118) (Filer)
- SECSagimet Biosciences Inc. filed SEC Form 8-K: Leadership Update, Other Events8-K - Sagimet Biosciences Inc. (0001400118) (Filer)
- PRSagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical OfficerSAN MATEO, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced the appointment of Andreas Grauer, MD, as Chief Medical Officer, effective April 20, 2026. Sagimet's prior Chief Medical Officer, Eduardo Bruno Martins, MD, DPhil, who will continue to support the Company as an external scientific advisor, has retired effective April 20, 2026. "We are delighted to welcome Dr. Andreas Grauer to our executive leadership team as Chief Medical Officer. Dr. Grauer has an extensive track record in leading clinical development
- PRSagimet Biosciences Announces Poster and Oral Presentations at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)SAN MATEO, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that a poster presentation and an oral presentation featuring analysis from the Phase 2b FASCINATE 2 trial of denifanstat in MASH will be delivered at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium being held April 12-15, 2026 in Vancouver, BC, Canada. MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium presentation details: Poster Title:Reduction of plasma glycine- and taurine-conjugated bile acids
- ANALYSTRodman & Renshaw initiated coverage on Sagimet Biosciences with a new price targetRodman & Renshaw initiated coverage of Sagimet Biosciences with a rating of Buy and set a new price target of $28.00
- SECSEC Form S-8 filed by Sagimet Biosciences Inc.S-8 - Sagimet Biosciences Inc. (0001400118) (Filer)
SGMT FAQ
6 questionsWhere does SGMT stock trade?
Sagimet Biosciences Inc. (SGMT) is listed on NASDAQ.What sector and industry is SGMT in?
Sagimet Biosciences Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Sagimet Biosciences Inc. go public?
Sagimet Biosciences Inc. (SGMT) completed its IPO in 2023.What are analysts saying about SGMT?
Sagimet Biosciences Inc. has had 8 recent analyst actions on file. The most recent action was from Rodman & Renshaw: Buy with a $2800.00 price target on 2026-03-26. Recent price targets range from $800.00 to $3000.00.What companies are similar to SGMT?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare SGMT side-by-side with any of them on Quantisnow.How can I track SGMT on Quantisnow?
Quantisnow aggregates Sagimet Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SGMT to receive live email and push alerts on every new disclosure.